The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Zygomycosis in Solid Organ Transplant Recipients: A Prospective, Matched Case‐Control Study to Assess Risks for Disease and Outcome
Open accessAbstract
BACKGROUND: Clinical characteristics, risks, and outcomes in solid organ transplant (SOT) recipients with zygomycosis in the era of modern immunosuppressive and newer antifungal agent use have not been defined. METHODS: In a matched case-controlled study, SOT recipients with zygomycosis were prospectively studied. The primary outcome measure was success (complete or partial response) at 90 days. RESULTS: Renal failure (odds ratio [OR], 3.17; P = .010), diabetes mellitus (OR, 8.11; P < .001), and prior voriconazole and/or caspofungin use (OR, 4.41; P = .033) were associated with a higher risk of zygomycosis, whereas tacrolimus (OR, 0.23; P = .002) was associated with a lower risk of zygomycosis. Liver transplant recipients were more likely to have disseminated disease (OR, 5.48; P = .021) and developed zygomycosis earlier after transplantation than did other SOT recipients (median, 0.8 vs 5.7 months; P < .001). Overall the treatment success rate was 60%. Renal failure (OR, 11.3; P = .023) and disseminated disease (OR, 14.6; P = .027) were independently predictive of treatment failure, whereas surgical resection was associated with treatment success (OR, 33.3; P = .003). The success rate with liposomal amphotericin B was 4-fold higher even when controlling for the aforementioned variables. CONCLUSIONS: The risks identified for zygomycosis and for disseminated disease, including those that were previously unrecognized, have implications for further elucidating the biologic basis and for optimizing outcomes in SOT recipients with zygomycosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcineurin is required for virulence of Cryptococcus neoformans
Odom, A., Muir, S., Lim, E., Toffaletti, D. L., Perfect, J., & Heitman, J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.10.2576 · Cited by 516
Calcineurin Is Essential for Candida albicans Survival in Serum and Virulence
Blankenship, J. R., Wormley, F. L., Boyce, M. K., Schell, W. A., Filler, S. G., Perfect, J. R., & Heitman, J. (2003) · Eukaryotic Cell · doi:10.1128/ec.2.3.422-430.2003 · Cited by 186
The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse
Omara, F. O., & Blakley, B. R. (1994) · British Journal of Nutrition · doi:10.1079/bjn19940094 · Cited by 89
Singh, N., & Sun, H.-Y. (2008) · Liver Transplantation · doi:10.1002/lt.21587 · Cited by 40
Self-citation
Cited by
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Self-citationEpidemiology and Clinical Manifestations of Mucormycosis
Petrikkos, G., Skiada, A., Lortholary, O., Roilides, E., Walsh, T. J., & Kontoyiannis, D. P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir866 · Cited by 1,452
Self-citationGlobal Epidemiology of Mucormycosis
Prakash, H., & Chakrabarti, A. (2019) · Journal of Fungi · doi:10.3390/jof5010026 · Cited by 938
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Self-citationIsavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704
Epidemiology and Diagnosis of Mucormycosis: An Update
Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020) · Journal of Fungi · doi:10.3390/jof6040265 · Cited by 687
Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006
Bitar, D., Van Cauteren, D., Lanternier, F., Dannaoui, E., Che, D., Dromer, F., Desenclos, J.-C., & Lortholary, O. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090334 · Cited by 429
Self-citationSkiada, A., Lanternier, F., Groll, A. H., Pagano, L., Zimmerli, S., Herbrecht, R., Lortholary, O., Petrikkos, G. L., & Leukemia*, O. B. O. T. T. E. C. O. I. I. (2013) · Haematologica · doi:10.3324/haematol.2012.065110 · Cited by 372
Self-citationCinnamaldehyde and its derivatives, a novel class of antifungal agents
Shreaz, S., Wani, W. A., Behbehani, J. M., Raja, V., Irshad, M., Karched, M., Ali, I., Siddiqi, W. A., & Hun, L. T. (2016) · Fitoterapia · doi:10.1016/j.fitote.2016.05.016 · Cited by 345
Invasive Non- Aspergillus Mold Infections in Transplant Recipients, United States, 2001–2006
Park, B. J., Pappas, P. G., Wannemuehler, K. A., Alexander, B. D., Anaissie, E. J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., et al. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110087 · Cited by 321
Emerging fungal infections in immunocompromised patients
Low, C.-Y., & Rotstein, C. (2011) · F1000 Medicine Reports · doi:10.3410/m3-14 · Cited by 309
Spellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr375 · Cited by 308
Healthcare-Associated Mucormycosis
Rammaert, B., Lanternier, F., Zahar, J.-R., Dannaoui, E., Bougnoux, M.-E., Lecuit, M., & Lortholary, O. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir867 · Cited by 282
Self-citationNocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study
Coussement, J., for the European Study Group for Nocardia in Solid Organ Transplantation, Lebeaux, D., for the European Study Group for Nocardia in Solid Organ Transplantation, van Delden, C., for the European Study Group for Nocardia in Solid Organ Transplantation, Guillot, H., for the European Study Group for Nocardia in Solid Organ Transplantation, Freund, R., for the European Study Group for Nocardia in Solid Organ Transplantation, et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw241 · Cited by 264
Self-citationChang, Z., & Heitman, J. (2019) · mBio · doi:10.1128/mbio.02579-19 · Cited by 202
Park, H.-S., Lee, S. C., Cardenas, M. E., & Heitman, J. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.004 · Cited by 168
Vallabhaneni, S., Benedict, K., Derado, G., & Mody, R. K. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw268 · Cited by 98
Chang, Z., Billmyre, R. B., Lee, S. C., & Heitman, J. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007957 · Cited by 72
“The etiologic causes of mucormycosis are the Mucoralean fungi, of which the three most common infectious genera are Rhizopus, Mucor, and Lichtheimia [7].”
BackgroundInvasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
Zilberberg, M. D., Shorr, A. F., Huang, H., Chaudhari, P., Paly, V. F., & Menzin, J. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-310 · Cited by 62
Antifungal combinations in Mucorales: A microbiological perspective
Schwarz, P., Cornely, O. A., & Dannaoui, E. (2019) · Mycoses · doi:10.1111/myc.12909 · Cited by 43
Metadata
- Authors
- Singh, N., Aguado, J. M., Bonatti, H., Forrest, G., Gupta, K. L., Safdar, N., John, G. T., Pursell, K. J., Muñoz, P., Patel, R., Fortun, J., Martin‐Davila, P., Philippe, B., Philit, F., Tabah, A., Terzi, N., Chatelet, V., Kusne, S., Clark, N., Blumberg, E., Julia, M. B., Humar, A., Houston, S., Lass‐Flörl, C., Johnson, L., Dubberke, E. R., Barron, M. A., & Lortholary, O.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-09-15
- Volume
- 200
- Issue
- 6
- Pages
- 1002-1011
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2140146047
- Cited by
- 233
- References
- 4
- FWCI
- 12.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.